Register Login
Register to leave comments
  • News bot May 7, 2026, 8:42 p.m.

    📋 JANUX THERAPEUTICS, INC. (JANX) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:16:20

    Event Type: Financial Results

    Event Details:

    JANUX THERAPEUTICS, INC. (JANX) Reports the reporting period Financial Results JANUX THERAPEUTICS, INC. (JANX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 3733
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 51828
      • JANX007 continues to enroll in its Phase 1b taxane
      • naïve patient population, including combination cohorts with darolutamide
      • Initiated clinical evaluation of JANX014, a double
        • targeting a validated solid tumor antigen, utilizing Janux’s TRACTr platform.•Recently announced development candidate nomination, triggering a $35 million milestone payment. Corporate & Leadership•Janux announced the appointment of William Go, M.D., Ph.D. as Chief Medical Officer, supporting the Company’s continued clinical advancement as additional programs enter the clinic in 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 10.66K 9.32K $1.34K +14.41%
    Current Assets Property Equipment Net 3.55K 3.85K $-306.00 -7.94%
    Current Assets Operating Lease Right Of Use Assets 17.87K 18.40K $-532.00 -2.89%
    Current Liabilities Accounts Payable 3.38K 4.97K $-1.59K -32.09%
    Operating Expenses Loss From Operations 34.21K 34.90K $-684.00 -1.96%
    Operating Expenses Net Loss 24.36K 23.51K $853.00 +3.63%
    Other Comprehensive Gain Loss Net Loss Per Share 0.39 0.38 $0.01 +2.63%
    Prepaid Expenses and Other Current Assets 10.66K 9.32K $1.34K +14.41%
    Property and Equipment, Net 3.55K 3.85K $-306.00 -7.94%
    Accounts Payable 3.38K 4.97K $-1.59K -32.09%
    Operating Lease Liabilities 2.47K 2.39K $79.00 +3.30%
    Loss from Operations 34.21K 34.90K $-684.00 -1.96%
    Net Loss 24.36K 23.51K $853.00 +3.63%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: JANUX THERAPEUTICS, INC.
    • Ticker Symbol: JANX

Search

News categories